• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169736 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
, u( n$ B; ?& B3 Z5 R3 \, G, y$ H3 M0 H5 i3 d- D; S

$ c( \' }4 `1 @' T/ d+ vSub-category:
% f: L! m. d  D) w: e$ g% |Molecular Targets ( ]/ `: P% O1 @
! i# P: J- @1 [* \7 a# D- ^
& J( f6 V( ], ~3 R7 t. A3 S2 y& ~
Category:  |8 @5 C! |2 }( @1 W4 l( P4 w
Tumor Biology
8 _# f$ A/ w3 {0 ~: B7 J, w: I$ i  M9 f7 v, K6 j9 c5 d5 i, n& A
& X* k3 n1 \; I2 h6 \  J$ o, c
Meeting:7 F! K* g  p5 D; M) h
2011 ASCO Annual Meeting 8 N( w5 _" O, I4 e% ]- }
5 O" @8 t- T' J; p
) B9 d! G! g/ B; `: B5 f- L
Session Type and Session Title:0 w6 n: D" M$ `% s1 @  b
Poster Discussion Session, Tumor Biology
8 W. s( y  Y5 t! g& q. X& F8 N$ \
% S" x1 o- j# _2 J( o& o) j, n2 l8 e- }8 p: k& V2 [) k1 M0 r
Abstract No:. g9 K' q( A+ h  o6 C+ r
10517 ( _; L2 w- k1 x

8 G% m! y; G& X& t# l
; {7 n$ h5 a! W# \) @9 A. kCitation:
0 c+ X3 E9 U$ RJ Clin Oncol 29: 2011 (suppl; abstr 10517)
: K% M) x5 A) d3 O" Z+ d- T; H
: a/ K3 z' o$ E6 y4 b4 D, }0 S. ~' _( t, T
Author(s):
* _4 u$ G: ^; f& f$ lJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , h  O( w- N) _  A* U) r) r6 q

! `% T2 P; M/ q$ v. m7 J6 D
2 o+ A. i0 y3 a9 n! ?& c9 F" A; Z, f% \; {) a6 H6 h$ k3 ?. U
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.' p- o" G" i+ Z

+ q1 G5 D0 l, @+ W: B0 AAbstract Disclosures1 r: Z$ {- {8 z* x/ e/ G$ ^
# M/ U% [& a0 W- V1 q" Q
Abstract:
4 B& l: B9 V0 R) W& \9 _( W. C; u0 U! S0 Z' V
' @8 U0 [6 N; n, b
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 @* A4 B2 J' t. t6 j0 K9 W4 a. \0 W4 I# |# ~- `0 [" ^% Z7 b: [
% s/ T% u0 z/ _7 Q8 ^
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 0 x. y  O3 j" A# s
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
3 k$ w$ U% R2 r0 v- n* Y, W; v
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
: M9 X% z0 S2 Z" Q- x! t& q5 f易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
1 {" ]1 d7 h2 R% P3 }ALK一个指标医院要900多 ...

9 _5 z2 P1 S& i* A' d7 k# f/ E平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
$ M$ c( R& S9 N7 i8 z- ?  T$ h, N9 {6 q1 x% ]8 X
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表